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Secreted mucins and cell-surface mucin-type common 0-glycan core structures can be syntheglycoproteins are rich in 0-glycans and are often sized ( Figure 1 ). Core 1 is the precursor strucresponsible for the expression of biologically ture for the synthesis of core 2, and core 3 is the important ligands and cancer-associated epiprecursor for core 4 [2] . All four common core topes. These epitopes may be recognized by antistructures may be elongated, sialylated, fucosybodies, soluble and cell-surface-bound lectins, lated, sulphated and carry blood-group determibacteria and viruses and may thus play important nants. The expression of particular much roles in the biology of cells. In cancer the exprescarbohydrate antigens depends on the cell-typesion of mucin epitopes may change and correlate specific relative activities of Golgi-localized with abnormal behaviour of cells. We have mx~~brane-bound glYcosYltransferases that may defined the biochemical basis for mucin epitope compete for common substrate structures, and changes in several model systems of cancer [l] .
the intracellular localization of transferases, as In normal mucin-secreting cells, four well as structural features of the substrates that are recognized by these enzymes. Enzyme activities may be regulated by many factors which are Abbreviation used: SA, sialic acid.
subjected to change in cancer, including the
I Biosynthesis of simple 0-glycans
The first step in the 0-glycosylation pathways i s the addition of GalNAc to Thr (or Ser) of the peptide substrate by polypeptide a-GalNAc-transferase (path a). Core I or core 3 may then be formed by core I P3-Gal-transferase (path c) and core 3 P3-GlcNAc-transferase (path d) respectively. Core 2 is synthesized from core I by core 2 P6-GlcNAc-transferase (L-type or M-type) (path e). Core 4 is synthesized from core 3 by core 4 P6-GlcNActransferase (path 9, which may be identical with core 2 /l6-GlcNAc-transferase (M-type). All common four core structures may be further converted, by sialylation. sulphation, fucosylation or elongation reactions. (Figure 1 ) although in vivo Ser is also glycosylated. The enzyme does not require a specific sequon in the substrate but the activity is influenced by the amino acid sequence as well as existing glycosylation of peptide substrates [7] . The dependence of this activity on the substrate structure explains the selective glycosylation of distinct Thr and Ser residues of glycoprotein substrates. The next enzyme acting in the 0-glycosylation sequence, core 1 P3-Galtransferase, requires GalNAc as a substrate to form core (Figure l) , and is also influenced by both the peptide structure and glycosylation pattern of the substrate [8] . This finding led to the proposal of site-directed processing of 0-glycans. Thus a change in the expression of individual glycoproteins in cancer cells may lead to altered glycosylation because enzymes processing O-glycans are variably active at different O-glycosylation sites.
In human breast cancer cells, the glycosylation of cancer-cell-surface mucin MUCl is reduced, and MUCl mucin epitopes are aberrantly exposed [9] . A number of anti-(mucin peptide) antibodies therefore bind to human breast cancer cells but not to normal human mammary cells. The abnormal exposure of peptide epitopes can be explained by an increase in a3-sialylation of 0-glycans. The activity of a3-sialyltransferase acting on Gall-3GalNAc (core 1) chains, as well as its mRNA levels, are increased in breast cancer cells compared with normal mammary cells. This activity is also increased in leukaemia cells of patients with chronic myelogenous leukaemia and acute myeloid leukaemia, compared with normal granulocytes [lo] , and in colon cancer tissue compared with normal adjacent tissue [ 111. a3-Sialylation of core 1 prevents elongation and branching but sialic acid may be added to the 6-position of the GalNAc moiety to form the common disialylated core 1 structure. This blocks the conversion into more complex 0-glycan structures. Recent studies indicate that a competition between branching and elongation reactions and sialylation could indeed take place since the a3-sialyltransferase was localized not only to the truns-Golgi but also to relatively early Golgi compartments [ 121. The increased sialylation therefore appears to be a general mechanism in cancer and leukaemia cells that leads to hypersialylation and premature termination and truncation of 0-glycan chains by competition with 0-glycan core 1 processing.
In most breast cancer cells, there is a conspicuous absence of core 2 P6-GlcNAc-transferase activity and its mRNA expression [9] ; this is consistent with the reduction of the GlcNAc content of cancer MUCl mucin [13] . This enzyme synthesizes the common 0-glycan core 2 structure GlcNAcfil-6 (GalPl-3) GalNAc and has to act before the a3-sialyltransferase. The absence of the core 2 structure leads to a significant reduction in the size of breast cancer mucin 0-glycans and contributes to the truncation of 0-glycan chains with a resulting exposure of underlying peptide epitopes.
Core 2 P6-GlcNAc-transferase in breast cancer cells is the L-type enzyme which was first described in acute and chronic myelogenous leukaemia cells [14] . The L-type enzyme is different from the M-type present in mucin-secreting tissues and has a much more restricted substrate-specificity. It synthesizes only 0-glycan core 2 whereas the M-type activity accepts a number of similar substrates into which it incorporates a GlcNAc P1-6 branch. The L-type activity is strongly inhibited by the p-nitrophenyl derivative of its core 1 substrate upon UV irradiation [15] . We have expressed the catalytic region without the transmembrane portion of the L-type core 2 86-GlcNAc-transferase in insect cells [16] . The recombinant enzyme is secreted into the insect cell medium. Two N-glycosylation sites near the N-terminus of the enzyme have to be occupied to form active stable enzyme. The enzyme acts early in the 0-glycosylation pathway to convert core 1 into core 2, before elongation, fucosylation, sialylation and sulphation of core 1. Once core 2 is formed, further conversions into complex 0-glycans can be catalysed, for example those carrying sialyl-Lewis" ligands for selectin interactions. Core 2 16-GlcNAc-transferase is thus important for the synthesis of complex 0-glycans and the presentation of its carbohydrate epitopes. In addition, the activity of the enzyme is regulated during differentiation [ 171 and activation of cells [18] , a well as in diseases Volume 25 [10, 19] . Studies of its regulation are therefore of great interest.
Sialyl-Tn (SAa2-6GalNAc-) and T n (Gal NAc-) antigens (Figure 1 ) are expressed on many cancer cells and are associated with poor prognosis in cancer patients [ZO] . GalNAc is found on all 0-glycans but is only exposed as the T n antigen in a selected population of cells. Possible reasons for the exposure of GalNAc are (a) a hyperactive polypeptide a-GalNAc-transferase or (b) a reduction in the normal process of GalNAc by core 1 P3-Gal-transferase or other enzymes that form simple core structures of 0-glycans. The mucin a6-sialyltransferase converts GalNAc into the sialyl-Tn antigen which is an end product in the biosynthetic pathway and cannot be converted further into complex structures. Mechanisms for the formation of sialyl-Tn antigen may be (a) an increase in a6-sialyltransferase activity localized to Golgi compartments where it can compete with chain elongation and branching, (b) a decrease in normal 0-glycan processing, for example by core 1 P3-Gal-transferase and core 3 P3-GlcNAc-transferase, (c) a relocalization of a6-sialyltransferase to earlier Golgi compartments or (d) a decrease in the 0-acetylation of sialic acids that can block the recognition of the sialyl-Tn antigen by antibodies
We have studied several model systems of colon cancer to determine the mechanism of sialyl-Tn and T n expression. In a model of human colon cancer, LSC and LSB cells, the expression of these T n antigens correlates with lower metastatic potential in athymic mice, supporting the hypothesis that complex 0-glycans, for example those carrying Lewis antigens, are involved in cell adhesion and the formation of metastases. Both LSC and LSB cells were isolated from LS174T cells but only LSC cells express T n antigens [22, 23] . The expression of T n antigens correlates with the loss of core 1 P3-Gal-transferase and core 3 P3-GlcNAc-transferase activity. Thus the common 0-glycan core structures 1 to 4 cannot be made in LSC cells, which are therefore committed to forming the truncated GalNAc structure and the sialyl-Tn antigen. The core 1 P3-Gal-transferase that is deficient in LSC cells cannot be activated by differentiation or in vivo growth of cells as a tumour. A deficiency of this enzyme has previously been described in human T-lymphocytic Jurkat cells [24] and in erythrocytes from patients with the T n syndrome [25] . In human
adenocarcinoma Caco-2 cells, the activity is reduced by enterocytic differentiation [ 171.
In contrast with the human model, it appears that in a rat colon cancer model it is not core 1 P3-Gal-transferase but rather mucin a6-sialyltransferase that regulates T n and sialyl-T n expression (I. Brockhausen, unpublished work). In rat colon cancer cell lines, the expression of sialyl-Tn correlates with the activity of mucin a6-sialyltransferase acting on GalNAcmucin, whereas core 1 P3-Gal-transferase is active even in sialyl-Tn antigen-expressing cells. These studies show that several possible mechanisms can lead to similar cell-surface expressions of cancer-associated antigens. The sialyltransferase itself appears to be regulated by differentiation of these cells in vitm. For an understanding of this regulation it will be important to determine the intracellular localization of the enzymes involved and to obtain an accurate measure of the in vivo activities.
Core 3 P3-GlcNAc-transferase, the enzyme synthesizing core 3, is expressed in a tissuespecific fashion and is enriched in normal colonic tissue [26] . Human colon cancer tissue exhibits reduced activity of the enzyme. The loss of the ability to synthesize core 3 may explain why the unmodified core 1 structure (T antigen) is expressed in colon cancer. Core 3 P3-GlcNActransferase has not yet been purified and is unstable in crude preparations. For reasons that are still unclear, the enzyme activity is lost from cultured cells, including those derived from colonic cancer tissue [27] . Colon cancer tissue also shows a number of other glycosyltransferase alterations [ 1 11. For example, core 2 P6-GlcNActransferase is less active, and is changed from the M-type expressed in normal tissues to the L-type prevalent in cancer. This switch is indicated by a decrease in the P6-GlcNAc-transferase activities synthesizing core 4 and the branch of the I antigenic determinant, relative to the activity synthesizing core 2. A number of cancer cell lines were analysed for these activities and their ratios vary in different cell lines. This may indicate that there are a number of different core 2 P6-GlcNAc-transferase enzymes which remain to be purified and cloned.
Mucins from colon cancer tissue are less sulphated than normal mucins [28] . Sulphated glycans may form effective ligands for selectin binding and may be involved in cell adhesion [29] but the significance of the undersulphation of cancer mucins is not yet known. 0-Glycan sulphation also regulates 0-glycan-processing reactions. We recently described a novel mucin sulphotransferase in colonic tissues that acts on the Gal residue of core 1 structures [30] . Core 2 formation is blocked after sulphation of core 1. The sulphotransferase activity is reduced in colon cancer tissue compared with normal colon, and is reduced in h u m a n breast cancer cells compared with normal mammary cells. I n a model of progression from human polyposis coli to tumorigenic cells, mucin sulphation as well a s the core 1 sulphotransferase activity decreased by about 80-90% [31] . Reduced sulphation therefore appears to be one of the characteristic features of cancer mucins. It is thought that several sulphotransferase activities are involved in the sulphation of mucin oligosaccharide chains. Purification and cloning of these enzymes may initiate studies of their importance in the regulation of cancer-specific antigens.
